Mostrando 8 resultados de: 8
Filtros aplicados
Publisher
Biomedicine and Pharmacotherapy(1)
Cell and Bioscience(1)
Current Pharmaceutical Design(1)
Expert Opinion on Drug Discovery(1)
Journal of Alzheimer's Disease(1)
Origen
scopus(8)
A chronological review of potential disease-modifying therapeutic strategies for Alzheimer's disease
ReviewAbstract: Late-onset Alzheimer’s disease (LOAD) is a neurodegenerative disorder that has become a worldwide hePalabras claves:Alzheimer’s disease, calcium, ER stress, glutamate, Neurodegeneration, neuroinflammation, Oxidative Stress, Parkinson’s DiseaseAutores:Antoni Camins, Auladell C., Busquets O., Espinosa-Jimenez T., Ettcheto M., Verdaguer E.Fuentes:scopusDexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusCurrent Research Therapeutic Strategies for Alzheimer's Disease Treatment
ReviewAbstract: Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the developed coPalabras claves:Autores:Abad S., Antoni Camins, Auladell C., Ettcheto M., Folch J., García M.L., Olloquequi J., Petrov D., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusDual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
ArticleAbstract: Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's disease (AD) but its iPalabras claves:Alzheimer's disease, APP/PS1 mice, EGCG, Epigallocatechin gallate, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Barroso E., Cano A., Chang J.H., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Souto E.M.B., Turowski P.Fuentes:scopusPI3 k/akt inhibition induces apoptosis through p38 activation in neurons
ArticleAbstract: Accumulating evidence suggests that the PI3 K/AKT pathway is a pro-survival signalling system in neuPalabras claves:Akt, BH3 only proteins, BIM, Dp5, LY294002, Neurons, p38 MAPKAutores:Antoni Camins, Auladell C., Folch J., Junyent F., Pallás M., Pelegrí Gabalda C., Vázquez De La Torre A., Verdaguer E., Vilaplana J., Zárate C.B.Fuentes:scopusMemantine for the treatment of dementia: A review on its current and future applications
ReviewAbstract: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the presence in the brainPalabras claves:Alzheimer's disease, Amyloid-protein, Extrasynaptic N-Methyl-D-aspartate receptor, Memantine, Tau proteinAutores:Antoni Camins, Auladell C., Busquets O., Casadesús G., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Olloquequi J., Pelegrí Gabalda C., Sanchez-Lopez E., Verdaguer E., Vilaplana J., Zárate C.B.Fuentes:scopusProtein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders
ReviewAbstract: Protein tyrosine phosphatase 1B (PTP1B) is a typical member of the PTP family, considered a direct nPalabras claves:Alzheimer's disease, insulin receptor, neurodegenerative diseases, neuroinflammation, Neurological disorders, PTP1B, Type 2 DiabetesAutores:Antoni Camins, Auladell C., Bulló M., Cano A., Carrasco M., Ettcheto M., Folch J., Fortuna A., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusThe preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
ArticleAbstract: Introduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor thPalabras claves:dyskinesia, entacapone, Opicapone, Parkinson’s Disease, tolcaponeAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopus